Urolon™ at the UKCS 2019 Meeting
We are pleased to announce that the 12-month follow-up data of our clinical study ‘Treatment with a polycaprolactone (PCL)-based bioresorbable urethral bulking agent for mild to moderate stress urinary incontinence (SUI)’ has been accepted for Oral Presentation (O14) on Thursday 25th of April 14:15-15:30h at the upcoming UKCS Meeting, 24-26 April 2019 in Manchester, United Kingdom.
Concluding message: The study shows that the Urolon™ treatment is safe and effective for women with mild to moderate SUI, resulting in improvements in both SUI severity and QoL. As the study is ongoing (up-to 2 years follow-up), more data will become available.
For more information, visit www.ukcsconferences.com